Key facts
- Notable investors include National Science Foundation Innovation Corps Program, Red Cedar Ventures, Small Business Innovation Research and Small Business Technology Transfer Programs.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Joule Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Joule Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Joule Therapeutics
Operator of a therapeutic technology platform intended to support energy-activated treatment of solid tumors. The company develops advanced cyanine-salt photosensitizers with selective tumor uptake, tunable photophysical properties, and near-infrared activation, enabling researchers and developers to assess imaging, safety, and preclinical efficacy for photodynamic therapy, boron neutron capture therapy, and treatment approaches for triple-negative breast cancer and other cancers.
- Sector
- Healthcare
- HQ
- East Lansing, MI, United States
- Employees
- 5
- Website
- jouletx.com/
- Ownership
- Privately Held (backing)
Joule Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Joule Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Joule Therapeutics in its N-PORT filings yet. We sweep new filings monthly.